IRulya Therapeutics, Inc. (IRLA)
32.95
+1.33
(+4.21%)
USD |
NASDAQ |
Oct 30, 16:00
33.50
+0.55
(+1.67%)
After-Hours: 20:00
IRulya Therapeutics Cash from Investing (Quarterly) : 8.001M for June 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 8.001M |
| March 31, 2026 | 12.00M |
| December 31, 2025 | 8.071M |
| September 30, 2025 | -1.781M |
| June 30, 2025 | 6.039M |
| March 31, 2025 | 10.90M |
| December 31, 2024 | 10.87M |
| September 30, 2024 | 7.105M |
| June 30, 2024 | -4.978M |
| March 31, 2024 | 8.914M |
| December 31, 2023 | 5.39M |
| September 30, 2023 | 3.635M |
| June 30, 2023 | -20.32M |
| March 31, 2023 | 5.54M |
| December 31, 2022 | 18.67M |
| September 30, 2022 | -8.826M |
| June 30, 2022 | -5.251M |
| Date | Value |
|---|---|
| March 31, 2022 | 13.41M |
| December 31, 2021 | 20.92M |
| September 30, 2021 | 0.766M |
| June 30, 2021 | 5.624M |
| March 31, 2021 | 31.64M |
| December 31, 2020 | 15.83M |
| September 30, 2020 | 10.37M |
| June 30, 2020 | -5.947M |
| March 31, 2020 | -72.68M |
| December 31, 2019 | 17.70M |
| September 30, 2019 | 9.222M |
| June 30, 2019 | -47.84M |
| March 31, 2019 | 3.164M |
| December 31, 2018 | |
| September 30, 2018 | |
| June 30, 2018 | -0.014M |
| March 31, 2018 | 0.00 |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Korsana Biosciences, Inc. | 0.00 |
| PepGen Inc. | -3.516M |
| Q32 Bio, Inc. | 0.00 |
| Bridgebio Oncology Therapeutics, Inc. | 45.73M |
| Arrowhead Pharmaceuticals, Inc. | 43.68M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -18.89M |
| Cash from Financing (Quarterly) | 108.93M |
| Free Cash Flow | -47.00M |
| Free Cash Flow Per Share (Quarterly) | -3.080 |
| Free Cash Flow to Equity (Quarterly) | -18.48M |
| Free Cash Flow to Firm (Quarterly) | -18.89M |
| Free Cash Flow Yield | -79.90% |